Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEHAW NASDAQ:APTX NASDAQ:CLVR NASDAQ:NEXI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEHAWAesther Healthcare Acquisition$0.00$0.01$0.06▼$0.33N/AN/A34,287 shsN/AAPTXAptinyx$0.10$0.08$0.01▼$0.72N/A1.271.32 million shs231,126 shsCLVRClever Leaves$0.00$0.00$0.00▼$2.65N/A3440.041,724 shs2 shsNEXINexImmune$0.02$0.00▼$7.05N/A1.946,478 shsN/AThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEHAWAesther Healthcare Acquisition0.00%0.00%-74.00%-86.32%-94.09%APTXAptinyx0.00%0.00%0.00%0.00%0.00%CLVRClever Leaves0.00%+100.00%-50.00%0.00%-99.99%NEXINexImmune0.00%0.00%0.00%0.00%-100.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAEHAWAesther Healthcare AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AAPTXAptinyxN/AN/AN/AN/AN/AN/AN/AN/ACLVRClever LeavesN/AN/AN/AN/AN/AN/AN/AN/ANEXINexImmuneN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEHAWAesther Healthcare Acquisition 0.00N/AN/AN/AAPTXAptinyx 0.00N/AN/AN/ACLVRClever Leaves 0.00N/AN/AN/ANEXINexImmune 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEHAWAesther Healthcare AcquisitionN/AN/AN/AN/AN/AN/AAPTXAptinyx$1MN/AN/AN/A$0.57 per shareN/ACLVRClever Leaves$17.42M0.00N/AN/A$14.02 per share0.00NEXINexImmuneN/AN/AN/AN/A$3.32 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEHAWAesther Healthcare AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/AAPTXAptinyx-$64.85M-$0.98N/AN/AN/AN/AN/AN/AN/ACLVRClever Leaves-$17.90M-$11.31N/A∞N/AN/AN/AN/AN/ANEXINexImmune-$32.34M-$18.54N/AN/AN/AN/A-534.32%-213.72%8/5/2025 (Estimated)Compare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEHAWAesther Healthcare AcquisitionN/AN/AN/AN/AN/AAPTXAptinyxN/AN/AN/AN/AN/ACLVRClever LeavesN/AN/AN/AN/AN/ANEXINexImmuneN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEHAWAesther Healthcare AcquisitionN/AN/AN/AAPTXAptinyxN/AN/AN/ACLVRClever LeavesN/AN/AN/ANEXINexImmuneN/A0.660.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEHAWAesther Healthcare AcquisitionN/AAPTXAptinyxN/ACLVRClever Leaves6.92%NEXINexImmune9.85%Insider OwnershipCompanyInsider OwnershipAEHAWAesther Healthcare AcquisitionN/AAPTXAptinyx10.97%CLVRClever Leaves8.20%NEXINexImmune14.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEHAWAesther Healthcare Acquisition2N/AN/ANot OptionableAPTXAptinyx12N/AN/ANot OptionableCLVRClever Leaves5601.76 million1.61 millionNo DataNEXINexImmune61.40 million1.19 millionNot OptionableAPTX, AEHAW, CLVR, and NEXI HeadlinesRecent News About These CompaniesNEXI-001 by NexImmune for Myelodysplastic Syndrome: Likelihood of ApprovalDecember 30, 2024 | pharmaceutical-technology.comPShattuck Labs stock craters following pipeline and job cutsOctober 2, 2024 | msn.comInfections the Main Cause of Nonrelapse Mortality After CAR-T for Blood CancersSeptember 5, 2024 | medpagetoday.comMNexImmune moves forward with wind-down processAugust 31, 2024 | bizjournals.comNexImmune adjourns special meeting to explore optionsAugust 4, 2024 | investing.comNEXI Stock Alert: NexImmune Delists From NasdaqJuly 12, 2024 | investorplace.comWhat Is Going on With NexImmune (NEXI) Stock Today?July 11, 2024 | investorplace.comNexImmune, Inc. Common Stock (NEXI) After-HoursMay 26, 2024 | nasdaq.comNEXI Stock Earnings: NexImmune Reported Results for Q1 2024May 20, 2024 | msn.comNanoengineering Approaches to the Design of Artificial Antigen-presenting CellsApril 20, 2024 | medscape.comMNEXI Stock Earnings: NexImmune Reported Results for Q4 2023April 17, 2024 | investorplace.comAcute Myeloid Leukemia Market Size is Expected to Grow by 2032 | DelveInsightApril 15, 2024 | theglobeandmail.comPortage mulls company closure, pauses enrolment for lead clinical programmeApril 15, 2024 | msn.comXilio fires 21% of its workforce and reprioritises pipelineApril 2, 2024 | msn.comInvestors grapple with more choices in big year for pharma fundraisingMarch 20, 2024 | pharmaceutical-technology.comPNexImmune Announces New Offerings in Recent Press ReleaseFebruary 7, 2024 | msn.comNexImmune Announces Closing of $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesFebruary 6, 2024 | markets.businessinsider.comNexImmune Secures Funding Through Equity and Warrant SalesFebruary 6, 2024 | msn.comNexImmune Ends Stock Sale Agreement, Raises $5.1 MillionFebruary 3, 2024 | msn.comNexImmune slips after securities offeringFebruary 2, 2024 | msn.comAPTX, AEHAW, CLVR, and NEXI Company DescriptionsAesther Healthcare Acquisition NASDAQ:AEHAW$0.0026 0.00 (0.00%) As of 07/18/2025Aesther Healthcare Acquisition Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in New York, New York.Aptinyx NASDAQ:APTXAptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Its lead product candidate NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat opioid use disorder, or OUD; and in preclinical trial for the treatment of alcohol use disorder, or AUD. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.Clever Leaves NASDAQ:CLVR$0.0002 0.00 (0.00%) As of 07/18/2025Clever Leaves Holdings Inc. operates in the botanical cannabinoid and nutraceutical industries. The company operates through two segments, Cannabinoid and Non-Cannabinoid. The Cannabinoid segment cultivates, extracts, manufactures, commercializes, and distributes cannabinoid products comprising cannabis flowers, cannabidiol isolates, full spectrum and standardized extracts, and dry smokable flowers internationally. The Non-Cannabinoid segment formulates, manufactures, markets, sells, distributes, and commercializes nutraceutical and other natural remedies, wellness products, detoxification products, and nutritional and dietary supplements for mass retailers, specialty and health retailers, and distributors in the United States. It also produces extracted products, including isolates, crude oil extracts, and oral solutions; and tetrahydrocannabinol flowers. The company serves retail distributors, pharmaceutical and cannabis companies, and pharmacies. Clever Leaves Holdings Inc. was founded in 2017 and is based in Tocancipá, Colombia.NexImmune NASDAQ:NEXINexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It provides NEXI-004 which is in preclinical stage for EBV related diseases; and NEXI005 designs for patient with specific targets for solid tumors. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
